Compare CAPR & PRCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | PRCH |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | 803 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2011 | 2019 |
| Metric | CAPR | PRCH |
|---|---|---|
| Price | $30.24 | $10.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $44.63 | $18.63 |
| AVG Volume (30 Days) | 968.6K | ★ 2.2M |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 90.91 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $482,414,000.00 |
| Revenue This Year | N/A | $4.15 |
| Revenue Next Year | $3.31 | $17.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.18 |
| 52 Week Low | $4.30 | $6.36 |
| 52 Week High | $40.37 | $19.44 |
| Indicator | CAPR | PRCH |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 60.72 |
| Support Level | $26.06 | $8.93 |
| Resistance Level | $30.06 | $11.19 |
| Average True Range (ATR) | 2.12 | 0.70 |
| MACD | -0.53 | 0.05 |
| Stochastic Oscillator | 19.86 | 67.86 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.